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DEEP VENOUS THROMBOSIS 
AND PULMONARY 
EMBOLISM AFTER LUNG 
TRANSPLANTATION 
The incidence of deep venous thrombosis or pulmonary embolism after 
lung or heart-lung transplantation has not been well defined. Pulmonary 
embolism may be of particular concern in the postoperative period owing to 
an inadequately developed or absent collateral bronchial circulation and 
potential risk of pulmonary infarction. Fourteen (12.1%) of 116 patients 
undergoing either lung (n = 87) or heart-lung (n = 29) transplantation 
developed thromboembolic complications 10 days to 36 months after 
operation. Deep vein thrombosis developed in nine patients, including three 
with upper body thrombosis related to indwelling central venous catheters. 
Seven patients (6%) had pulmonary embolism, and three of them died. 
Resolution of pulmonary embolism was successfully accomplished by 
selective pulmonary artery infusion of urokinase in three patients without 
complications. Our experience indicates that deep vein thrombosis and 
pulmonary embolism are significant problems after lung transplantation. 
Mortality is high in those patients in whom pulmonary embolism develops. 
Therefore, a comprehensive prevention protocol is warranted. (J THORAC 
CARDIOVASC SURG 1995;110:540-4) 
Timothy J. Kroshus, MD, Vibhu R. Kshettry, MD, Marshall I. Hertz, MD, 
and R. Morton Bolman III, MD, Minneapolis, Minn. 
V enous thromboembolism is a common occur- rence in patients undergoing surgery. It has been 
estimated that deep venous thrombosis (DVT) and 
pulmonary embolism (PE) result in 300,000 to 
600,000 hospitalizations per year in the United 
States and that 50,000 to 100,000 of these patients 
die of PE. 1' 2, 3 Limited reports are available regard- 
ing the incidence of thromboembolism after cardiac 
surgery or thoracotomy. The incidence of DVT after 
major surgical operations in patients older than 40 
years of age is at least 30% in the absence of 
prophylactic measures. 4 The overall incidence of PE 
after cardiac operations was noted to be 0.56% in 
one report. 5 Thromboembolic events (DVT/PE) 
were noted in 26% of patients after pulmonary 
resection in another report? No reports have de- 
scribed the occurrence of thromboembolism after 
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lung transplantation. The purpose of this report is to 
describe the incidence and course of thromboem- 
bolic events in a population of patients undergoing 
lung transplantation. 
Methods 
Patients. The clinical courses of 116 consecutive pa- 
tients who underwent lung (n = 87) or heart-lung (n = 29) 
transplantation at the University of Minnesota Hospital 
and Clinic between June 1986 and December 1993 were 
retrospectively reviewed to determine the incidence, diag- 
nostic methods used, treatment, and outcome in those 
having thromboembolic complications. Fourteen patients 
had thromboembolic complications, including 11 women 
and 3 men, with an age range of 5 to 59 years. Patients were 
categorized by primary disease, transplantation procedure 
performed, and thromboembolic event (Table I). Pretrans- 
plantation risk factors were evaluated, including previous 
venous thromboembolic events, polycythemia, heart failure, 
oral contraceptives, and recent myocardial infarction. 
Diagnostic methods. All lung transplant recipients un- 
derwent postoperative x non ventilation-perfusion (V/Q) 
scanning between postoperative days 7 and 10 as part of 
our routine posttransplantation evaluation. In addition, 
follow-up V/Q scans were done at 6 months and 1 year 
after transplantation. Suspicion of PE prompted a chest 
radiograph and repeat V/Q scan. V/Q scans were rated as 
low, indeterminate, or high probability based on Blobiello 
criteria. Change from a previous V/Q scan was considered 
significant, as was an unmatched perfusion defect. The 
diagnosis of PE was confirmed by pulmonary angiography 
in four patients and by autopsy in another. Two other 
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Table I. Pn!mary disease and complication 
Procedure Primary disease Age Sex Complication 
LSL Primary pulmonary HTN 51 F DVT × 4/PE 
LSL al-antitrypsin 45 F DVT 
BSL Idiopathic pulmonary fibrosis 42 F DVT 
LSL al-antitrypsin 58 F PE x 2/DVT × 2 
LSL Chronic obstructive pulmonary disease 58 F PE 
LSL al-antitrypsin 47 M PE 
BSL Primary pulmonary HTN 30 F PE 
LSL Chronic obstructive pulmonary disease 46 F DVT 
RSL al-antitrypsin 58 M DVT 
HL al-antitrypsin 54 F PE 
RSL Idiopathic pulmonary fibrosis 59 M PE 
HL al-antitrypsin 47 F DVT 
LSL; BSL Primary pulmonary HTN 4 F DVT 
BSL Primary pulmonary HTN 40 F DVT 
BSL, Bilateral single lung transplantation; DV'/;, deep venous thrombosis; F, female; HL, heart-lung transplantation; HTN,, hypertension; LSL, left single lung 
transplantation; M, male; PE, pulmonary embolism; RSL, right single lung transplantation. 
patients had a presumed iagnosis based on the presence 
of small unmatched perfusion defects on follow-up V/Q 
scans that were different from previous V/Q scan findings. 
These two patients were in clinically stable condition and 
were treated with anticoagulation with close follow-up. 
One of these patients was considered for pulmonary 
angiography, but the test was not performed because of 
renal insufficiency. 
In addition, all patients with suspected PE underwent 
lower extremity duplex ultrasonic scanning in an attempt 
to find the origin of the PE. Those with negative results of 
lower extremity duplex ultrasonography underwent upper 
body ultrasonography if indwelling central venous cathe- 
ters were present. 
Patients who had extremity swelling underwent duplex 
ultrasonography for diagnosis of DVT. No patient under- 
went venography for diagnosis. Close follow-up was per- 
formed in those patients with diagnosis of a thromboem- 
bolic event. Se.rial chest roentgenograms and V/Q scans were 
obtained every 1 to 2 weeks until resolution was noted. 
Results 
A total of 14 patients had 21 events, including 7 
with DVT, 5; with PE, and 2 with both DVT and PE. 
One patient had five events (one PE and four 
DVTs) and another patient had 4 events (two PEs 
and two DVTs). The former patient was considered 
to be at increased risk before transplantation be- 
cause o f  a history of superficial thrombophlebitis. 
Patients witl~ DVT had unilateral extremity swelling 
and pain r Five patients had documented lower ex- 
tremity DVT and were initially treated with antico- 
agulation. This was poorly tolerated in two patients 
because of bleeding complications and recurrence of 
DVT despite therapeutic anticoagulation parame- 
ters, eventually necessitating placement of an infe- 
rior vena cava filter (Vena Tech LGM vena caval 
filter system, B. Braun Biotech, Allentown, Pa.). 
One patient had a history of DVT and filter place- 
ment 6 months before transplantation. This patient 
had a recurrent DVT in the same location in the 
proximal left superficial femoral vein 2 months after 
transplantation. An additional patient was consid- 
ered to be at possible increased risk because of a 
history of lower extremity superficial thrombophle- 
biffs. Upper body DVT developed in three patients, 
including one with left subclavian vein thrombosis 
and two with right internal jugular vein thrombosis. 
All upper body DVT episodes were associated with 
indwelling central venous catheters, and all were 
treated by catheter emoval and anticoagulation 
with heparin and warfarin. Follow-up duplex ultra- 
sound scanning was performed every 1 to 2 weeks 
until thrombus resolution was ensured. 
Clinical features of patients with PE are summa- 
rized in Table II. Of the seven patients experiencing 
PE, three died (43%). One died suddenly 22 days 
after transplantation from a saddle embolism that 
occurred after the patient was discharged from the 
hospital. Another patient experienced PE 11 days 
after transplantation and eventually died on the 
twenty-first postoperative day of infectious compli- 
cations and multiple organ failure syndrome. In an 
additional patient PE developed 2 months after 
transplantation and was successfully treated with 
urokinase followed by placement of an inferior vena 
cava filter. A recurrent PE occurred at 12 months 
after transplantation, and the patient died 4 weeks 
later of progressive organ failure and sepsis. 
Four patients with PE survived (see Table II). 
Two demonstrated no deterioration of pulmonary 
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Table II. Time after transplant, treatment, and 
outcome by event 
Time after 
Event transplantation Treatment Outcome 
PE/DVT 38 days Anticoagulation Resolved 
DVT 12 mo Anticoagulation Resolved 
DVT 13 mo Anticoagulation Resolved 
Thrombophlebitis 36 mo IVC filter Resolved 
DVT 19 days IVC filter Resolved 
DVT 22 mo Anticoagulation Resolved 
PE/DVT 2 mo Urokinase/ Resolved 
IVC filter 
DVT 4 mo Anticoagulation Resolved 
PE 12 mo Anticoagulation Death 
PE 22 days Anticoagulation Death 
PE 10 days Urokinase/ Death 
IVC filter 
PE 12 mo Anticoagulation Resolved 
DVT 2 mo Anticoagulation/I Resolved 
VC filter 
DVT 2 mo Anticoagulation Resolved 
PE 8 mo Urokinase Resolved 
PE 5 mo Anticoagulation/ Resolved 
IVC filter 
DVT 1 mo Remove central Resolved 
line 
DVT 7 mo Remove central Resolved 
line 
DVT 21 days Remove central Resolved 
line 
DVT;, Deep venous thrombosis;/VC, inferior vena cava; PE, pulmonary 
embolism. 
function after recovery from their event, and one 
later died of bronchiolitis obliterans. The fourth 
patient died 1 year after the PE event of an unre- 
lated cause. The PE originated from the lower 
extremity in one patient, from the left upper extrem- 
ity in one patient, and from thrombus urrounding a 
central venous catheter in one patient. Origin was 
unknown in four patients. Presenting symptoms in 
patients with PE included pleuritic hest pain in two 
patients and cardiac arrhythmias in two patients 
(atrial fibrillation in one and supraventricular tachy- 
cardia in one); one patient had massive hemoptysis 
and acute respiratory arrest with immediate death 
from a saddle embolism. 
Treatment of patients after a diagnosis of throm- 
boembolic omplications consisted of initial hepa- 
rinization followed by oral anticoagulation with war- 
farin, maintaining the prothrombin time at 1.5 to 2 
times normal. Three patients underwent 24 to 48 
hours of selective urokinase infusion by pulmonary 
artery catheter placement after confirmation of PE 
by pulmonary angiography. There were no docu- 
mented complications related to the use of uroki- 
nase or pulmonary artery catheter placement in any 
of these patients. Follow-up pulmonary angiography 
at 12- to 24-hour intervals after initiation of uroki- 
nase revealed almost complete resolution of throm- 
bus in two patients and complete resolution in the 
other patient. These patients were then anticoagu- 
lated with heparin followed by warfarin. Those pa- 
tients not able to tolerate oral anticoagulation r who 
had additional thromboembolic events while undergo- 
ing therapeutic anticoagulation u derwent placement 
of an inferior vena cava filter (n = 4). No patient in 
this review underwent pulmonary embolectomy. 
Discussion 
Our findings suggest hat lung transplant recipi- 
ents constitute a high-risk group for DVT and 
subsequent PE. The significance of this problem is 
obvious because this group of patients cannot afford 
the threat of infarction of lung tissue after trans- 
plantation. The risk of infarction from a PE is 
greatest in the immediate perioperative period be- 
cause the newly transplanted lung does not have an 
alternate blood supply owing to the lack of a bron- 
chial circulation. In addition, despite the redevelop- 
ment of bronchial collaterals with time, this blood 
supply may not be sufficient o meet the require- 
ments of the transplanted lung and prevent infarc- 
tion if a PE occurs later in the postoperative p riod. 
Little information is available regarding the inci- 
dence and significance of DVT and PE after lung 
transplantation. It is known that the incidence of 
DVT after major surgical operations i at least 30% 
for patients older than 40 years of age if no prophy- 
lactic measures are used. 4This incidence is dramat- 
ically reduced with the use of prophylactic measures. 
The incidence of clinically significant PE has been 
reported as 1.6% in the general surgical population, 
with the likelihood of a major PE leading to death 
approaching 1%. 6 One study that analyzed 144 
patients who experienced PE revealed mortality in 
12 patients (8%); in 4 patients (3%), the PE was 
determined to be the primary cause of death. 7
Several acquired and inherited risk factors for the 
development ofDVT and PE have been recognized. 
Lung transplant recipients often fulfill some of the 
elements of Virchow's classic triad of stasis, endo- 
thelial injury, and hypercoagulability. A period of 
immobilization and ventilator dependence immedi- 
ately after transplantation leads to lower extremity 
venous stasis. In addition, these patients usually 
have indwelling central venous lines for monitoring 
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and access, all of which can predispose patients to 
DVT. Acquired risk factors predisposing to 
DVT/PE include major surgical procedures result- 
ing in patient immobilization and medical diseases 
associated with abnormalities of coagulation and 
fibrinolysis, platelet abnormalities, and blood vessel 
disorders.6, 8 Inherited disorders include protein C 
deficiency, 9 protein S deficiency, x°antithrombin III 
deficiency,11, 2dysfibrinogenemia,13 and disorders 
of plasminogen and plasminogen activationJ 4'15 In 
addition, patients undergoing lung transplantation 
may have pulmonary hypertension, which may con- 
stitute a risk factor, although right-sided heart pres- 
sures usually return to near normal levels after 
transplantation. It is important o recognize those 
patients at increased risk before transplantation to
administer adequate prophylaxis during the periop- 
erative and postoperative periods. Those patients 
who have had previous thromboembolic events con- 
stitute an extremely high-risk group for recurrence. 
One patient in our series was identified to be at 
increased risk before transplantation because of a 
history of DVT, and another was considered to be at 
increased risk because of a history of superficial 
thrombophlebitis. 
In our series, symptomatic PE developed in 7 
(6%) of 116 patients, and 3 (43%) of the 7 died. The 
primary cause of death was determined to be PE in 
only one patient; the other two patients died 10 days 
and 4 weeks later, respectively, of infectious compli- 
cations. Clearly, the PE was the inciting event in the 
fatal course ,experienced by each of these patients. 
Diagnosis of PE continues to be a difficult prob- 
lem. A high index of suspicion and low threshold for 
obtaining diagnostic tudies hould exist on the basis 
of clinical impression. Initial investigations consist 
of a chest roentgenogram, V/Q scan, and lower 
extremity duplex ultrasonic scanning. If clinical sus- 
picion is high and the V/Q scan shows high proba- 
bility, patients should undergo pulmonary angiogra- 
phy for definitive diagnosis. Patients who are not 
candidates for pulmonary angiography should be 
aggressively treated on the basis of clinical impres- 
sion and initial diagnostic study results. The diffi- 
culty in diagnosing PE remains with those patients 
who have indeterminate V/Q scan results. These 
patients hould be referred for pulmonary angiog- 
raphy if clinical suspicion is high and there is support- 
ing evidence of DVT on duplex ultrasonic scanning. If 
V/Q scan results are of low probability and duplex 
ultrasonic scanning results are negative, patients may 
safely be observed if clinical suspicion is low. 
The importance of noninvasive duplex ultra- 
sonography for detection of DVT cannot be over- 
looked. It has been reported that more than 90% of 
PEs originate in the proximal lower extremities. 16In 
our series, a significant number of patients had 
negative lower extremity duplex ultrasound results 
but were found to have thrombus urrounding upper 
body indwelling central venous catheters. We con- 
duct an aggressive search for DVT in both the lower 
extremities and surrounding central lines in all 
patients with suspicion of PE by means of duplex 
ultrasonography. No patient in our series underwent 
contrast venography for diagnosis of DVT. 
If PE is confirmed angiographically and the 
thrombus is occlusive of several pulmonary seg- 
ments, directed pulmonary artery urokinase infusion 
can be performed successfully, as demonstrated in 
three of our patients. Urokinase infusion has been 
shown to be effective when it is administered by a 
peripheral intravenous route or intraarterially. 
However, the collateral bronchial circulation may 
not be adequately developed, and in the lung trans- 
plant recipient it is absent. Therefore, we used a 
directed pulmonary tery infusion in an attempt to 
obtain clot resolution as quickly as possible because 
of the potential risk of lung infarction. There was no 
morbidity or mortality related to pulmonary artery 
urokinase infusion in these patients. 
Prophylaxis of DVT and PE is a critical compo- 
nent of the management of patients after lung 
transplantation. Subcutaneous heparin and pneu- 
matic compression devices have both been shown to 
decrease the incidence and subsequent morbidity 
and mortality of DVT and PE. In general, the use of 
aspirin has not been shown to add a protective 
effect, 6although the incidence of thromboembolism 
after thoracotomy for carcinoma was markedly de- 
creased in patients receiving aspirin or ibuprofen in 
one study. 3We have adopted a program of periop- 
erative and postoperative subcutaneous heparin ad- 
ministration extending until the time of discharge. 
Pneumatic ompression garments are used during and 
after the operation until the patient is ambulatory. 
After patients are ambulatory, they receive antiplatelet 
agents. Those patients having thromboembolic events 
initially receive intravenous heparin until clot resolu- 
tion, followed by oral anticoagulants (warfarin). Re- 
current DVT/PE during therapeutic anticoagulation, 
intolerance of oral anticoagulants, or presence of a 
proximal ower extremity DVT in a patient prompts 
consideration of an inferior vena cava filter. 
The true incidence of PE in this patient popula- 
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tion is not known. Many patients may have had 
small and clinically silent PEs, or the PE may lodge 
in the native lung in patients with single lung 
transplants in whom clinical symptoms may not be 
produced. The diagnosis of a PE to the native lung 
in single lung transplant recipients is an especially 
difficult problem diagnostically because chest roent- 
genography and V/Q scan findings are frequently 
abnormal in the native lung. After diagnosis and 
treatment of PE or DVT, all patients should un- 
dergo close follow-up, with duplex ultrasonography 
and V/Q scanning performed every 1 to 2 weeks 
until resolution, and then be followed up on a 
routine basis. Oral anticoagulant medications 
should be continued indefinitely as long as they are 
tolerated without serious side effects. 
The risk of thromboembolic complications ex- 
tends well into the postoperative period, including 
the period after discharge from the hospital. It also 
appears that the greatest risk for the development of
DVT is in the period immediately after prophylaxis 
is discontinued. In this series, thromboembolic com- 
plications occurred from 10 days to 36 months after 
transplantation, with most events occurring after 
discharge from the hospital. This delay underscores 
the importance of continued surveillance and a 
heightened awareness for these events after the 
patient has been discharged from hospitalized care. 
The need for prophylaxis may continue well into the 
postoperative period. 
In summary, thromboembolic complications re- 
main a serious problem for the lung transplant 
recipient, and a comprehensive prevention protocol 
is warranted. Prophylaxis needs to extend well into 
the posttransplantation period, including the period 
after discharge from the hospital. A high index of 
suspicion is necessary to allow early diagnosis and 
successful treatment of these potentially fatal disor- 
ders. The true incidence of DVT/PE remains un- 
known in this patient population and may extend 
late into the postoperative period, including the 
period after discharge from the hospital. A multi- 
center trial to address the efficacy and cost-effective- 
ness of a follow-up screening program for the de- 
tection of clinically silent DVT may be helpful. 
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